IP Library › Granted Patent US 11,702,474
Granted Patent B2
US 11,702,474 · App. 17/120,935 · Granted Jul 18, 2023

Antibodies specific for CD47, PD-L1, and uses thereof

Inventors: Javier Fernando Chaparro Riggers (San Mateo, CA); Shih-Hsun Chen (San Diego, CA); Sheng Ding (Foster City, CA); Pawel Kamil Dominik (San Diego, CA); Shahram Salek-Ardakani (La Jolla, CA); Jessica Lynn Stanfield (San Diego, CA); Thomas John Van Blarcom (Oakland, CA)
Assignee: Pfizer Inc.
C07K16/2827A61P35/00C07K16/2803A61K2039/505C07K2317/31C07K2317/33C07K2317/51C07K2317/515C07K2317/52C07K2317/56C07K2317/73C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,702,474
App. No.
17/120,935
Granted
Jul 18, 2023
Kind
B2
Abstract

Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.

Claims (40)

1. An isolated antibody that specifically binds to CD47 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises (i) a VH complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 13, 14, or 15; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or 17; (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 18; (iv) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (v) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (vi) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 21.

2. The antibody of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 1.

3. The antibody of claim 1 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 2.

4. The antibody of claim 1 , wherein the antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence as shown in SEQ ID NO: 1 and a light chain variable region (VL) comprising the amino acid sequence as shown in SEQ ID NO: 2.

5. An isolated antibody that specifically binds to PD-L1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises (i) a VH complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 41, 42, or 43; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44 or 45; and (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 46; (iv) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (v) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (vi) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 21.

6. The antibody of claim 5 , wherein the VH comprises the sequence of SEQ ID NO: 4.

7. The antibody of claim 5 , wherein the VL comprises the sequence of SEQ ID NO: 2.

8. The antibody of claim 5 , wherein the antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence as shown in SEQ ID NO: 4 and a light chain variable region (VL) comprising the amino acid sequence as shown in SEQ ID NO: 2.

9. The antibody of claim 1 , wherein the antibody is a bispecific antibody.

10. The antibody of claim 9 , wherein the bispecific antibody specifically binds to CD47 and PD-L1.

11. The antibody of claim 10 , wherein the antibody comprises a first antigen binding portion and a second antigen binding portion, wherein the first antigen binding portion specifically binds to CD47 and the second antigen binding portion specifically binds to PD-L1, wherein the first antigen binding portion comprises a first antigen binding portion VH and a first antigen binding portion VL, wherein the second antigen binding portion comprises a second antigen binding portion VH and a second antigen binding portion VL, and wherein the amino acid sequence of the first antigen binding portion VL and the amino acid sequence of the second antigen binding portion VL have the same amino acid sequence.

12. The antibody of claim 11 , wherein the amino acid sequence of the first antigen binding portion VL and the amino acid sequence of the second antigen binding portion VL each comprise the amino acid sequence as shown in SEQ ID NO: 2.

13. An isolated bispecific antibody comprising a first antigen binding portion that specifically binds to CD47 and a second antigen binding portion that specifically binds to PD-L1, wherein the first antigen binding portion comprises a first antigen binding portion VH and a first antigen binding portion VL, wherein the second antigen binding portion comprises a second antigen binding portion VH and a second antigen binding portion VL, and wherein:

a) the first antigen binding portion VH comprises (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13, 14, or 15; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or 17; and (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 18;

b) the first antigen binding portion VL comprises (i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (iii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 21;

c) the second antigen binding portion VH comprises (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 41, 42, or 43; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44 or 45; and (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 46; and

d) the second antigen binding portion VL comprises (i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (iii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 21.

14. The bispecific antibody of claim 13 , wherein:

a) the first antigen binding portion VH comprises the amino acid sequence of SEQ ID NO: 1;

b) the first antigen binding portion VL comprises the amino acid sequence of SEQ ID NO: 2;

c) the second antigen binding portion VH comprises the amino acid sequence of SEQ ID NO: 4; and

d) the second antigen binding portion VL comprises the amino acid sequence of SEQ ID NO: 2.

15. The bispecific antibody of claim 13 , wherein the bispecific antibody comprises a Fc domain.

16. The bispecific antibody of claim 15 , wherein the Fc domain is an IgG1 Fc domain, IgG2 Fc domain, or an IgG4 Fc domain.

17. The bispecific antibody of claim 15 , wherein the Fc domain comprises a first Fc chain and a second Fc chain, and wherein the first Fc chain and the second Fc chain contain one or more modifications promoting the association of the first Fc chain with the second Fc chain.

18. The bispecific antibody of claim 15 , wherein the antibody comprises an anti-CD47 heavy chain comprising the amino acid sequence of SEQ ID NO: 61 and the antibody comprises an anti-PD-L1 heavy chain comprising the amino acid sequence of SEQ ID NO: 64.

19. The bispecific antibody of claim 15 , wherein the antibody comprises an anti-CD47 light chain comprising the amino acid sequence of SEQ ID NO: 62 and an anti-PD-L1 light chain comprising the amino acid sequence of SEQ ID NO: 62.

20. The bispecific antibody of claim 15 ,

wherein the antibody comprises a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain;

wherein the first antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the second antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 64; and

wherein both the first antibody light chain and the second antibody light chain comprise the amino acid sequence of SEQ ID NO: 62.

21. The bispecific antibody of claim 13 , wherein the affinity of the anti-PD-L1 antigen binding portion for PD-L1 is greater than the affinity of the anti-CD47 antigen binding portion for CD47.

22. A pharmaceutical composition comprising a therapeutically effective amount of the antibody of any one of claims 1 - 8 or the bispecific antibody of any one of claim 9 - 13 , 14 , or 15 - 21 , and a pharmaceutically acceptable carrier.

23. The antibody of claim 5 , wherein the antibody is a bispecific antibody.

24. The antibody of claim 23 , wherein the bispecific antibody specifically binds to CD47 and PD-L1.

25. The antibody of claim 24 , wherein the antibody comprises a first antigen binding portion and a second antigen binding portion, wherein the first antigen binding portion specifically binds to CD47 and the second antigen binding portion specifically binds to PD-L1, wherein the first antigen binding portion comprises a first antigen binding portion VH and a first antigen binding portion VL, wherein the second antigen binding portion comprises a second antigen binding portion VH and a second antigen binding portion VL, and wherein the amino acid sequence of the first antigen binding portion VL and the amino acid sequence of the second antigen binding portion VL have the same amino acid sequence.

26. The antibody of claim 25 , wherein the amino acid sequence of the first antigen binding portion VL and the amino acid sequence of the second antigen binding portion VL each comprise the amino acid sequence as shown in SEQ ID NO: 2.

27. An isolated bispecific antibody that specifically binds to CD47 and PD-L1, wherein the antibody comprises a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain;

wherein the first antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the second antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 64; and

wherein both the first antibody light chain and the second antibody light chain comprise the amino acid sequence of SEQ ID NO: 62.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →